Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Mutations in the ABCD1 gene cause the clinical spectrum of the neurometabolic disorder X‐linked adrenoleukodystrophy/adrenomyeloneuropathy (X‐ALD/AMN). Currently, the most efficient therapeutic opportunity for patients with the cerebral form of X‐ALD is hematopoietic stem cell transplantation and possibly gene therapy of autologous hematopoietic stem cells. Both treatments, however, are only accessible to a subset of X‐ALD patients, mainly because of the lack of markers that can predict the onset of cerebral demyelination. Moreover, for female or male X‐ALD patients with AMN, currently only unsatisfying therapeutic opportunities are available. Thus, this review focuses on current and urgently needed future pharmacological therapies. The treatment of adrenal and gonadal insufficiency is well established, whereas applications of immunomodulatory and immunosuppressive drugs have failed to prevent progression of cerebral neuroinflammation. The use of Lorenzo's oil and the inefficacy of lovastatin to normalize very‐long‐chain fatty acids in clinical trials as well as currently experimental and therefore possible future therapeutic strategies are reviewed. The latter include pharmacological gene therapy mediated by targeted upregulation of ABCD2, the closest homolog of ABCD1, antioxidative drug treatment, small molecule histone deacetylase inhibitors such as butyrates and valproic acid, and other neuroprotective attempts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040 · cited 1×
“This family of enzymes is now also appropriately being referred to as lysine deacetylases (KDACs) to include their function on non-histone, lysine-containing targets (16), which among others include transcription factors (e.”
BackgroundHistone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationHalliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703 · cited 1×
“Some recent evidence even suggests that this phenomenon is an early event and may play a role in the pathogenesis of several neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease or amyotrophic lateral sclerosis (90, 113).”
BackgroundMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Halliwell, B. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02075-4 · Cited by 655 · cited 1×
“Pitfalls include: (i) endogenous levels of antioxidants in the treated patients were not controlled, and this is of importance as patients might react differently to antioxidants based on baseline levels; (ii) the in vivo antioxidant effects of the drug and patients compliance were not monitored (39); (iii) the causal…”
BackgroundAdrenoleukodystrophy: A Clinical and Pathological Study of 17 Cases
Schaumburg, H. H. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510033001 · Cited by 475
Brichta, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg256 · Cited by 382
Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., & Moser, H. W. (2001) · Annals of Neurology · doi:10.1002/ana.101 · Cited by 324
Research works printed but not linked: 69
- 10.1016/S0014-5793(97)00122-1 · DOI · Paper page
- 10.1016/S0167-4781(00)00291-8 · DOI · Paper page
- 10.1046/j.1526-0968.2000.004005338.x · DOI
- 10.1016/j.bbamcr.2006.07.010 · DOI · Paper page
- 10.1016/j.freeradbiomed.2008.04.005 · DOI
- 10.1046/j.1471-4159.2001.00647.x · DOI · Paper page
- 10.1016/S0014-5793(00)01852-4 · DOI
- 10.1111/j.1750-3639.2010.00394.x · DOI · Paper page
- 10.1182/blood.V84.1.339.339 · DOI · Paper page
- 10.1212/WNL.58.6.901 · DOI · Paper page
- 10.1001/archneur.64.5.659 · DOI · Paper page
- 10.1056/NEJMc0907735 · DOI · Paper page
- 10.1016/j.nbd.2009.07.019 · DOI · Paper page
- 10.1016/S0014-5793(99)00379-8 · DOI · Paper page
- 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W · doi:10.1002/(sici)1097-4547(19971201)50:5<829::aid-jnr19>3.0.co;2-w
- 10.1124/mol.63.6.1296 · DOI
- 10.1093/hmg/ddq082 · DOI · Paper page
- 10.1016/j.neures.2009.05.002 · DOI · Paper page
- 10.1016/j.jsbmb.2009.04.006 · DOI
- 10.1083/jcb.200501036 · DOI · Paper page
- 10.1016/j.bbadis.2004.04.001 · DOI
- 10.1111/j.1471-4159.2006.03868.x · DOI · Paper page
- 10.1517/13543784.17.2.169 · DOI · Paper page
- 10.1016/j.yexcr.2008.10.031 · DOI
- 10.1038/nrd2681 · DOI · Paper page
- 10.1111/j.1471-4159.2008.05513.x · DOI · Paper page
- 10.1038/nn.2471 · DOI · Paper page
- 10.1073/pnas.97.2.817 · DOI · Paper page
- 10.1023/A:1005361607523 · DOI · Paper page
- Köhler W, 2005, Understanding and Treating Adrenoleukodystrophy. Present State and Future Perspectives, 28
- 10.1373/49.2.230 · DOI · Paper page
- 10.1016/j.taap.2007.09.014 · DOI
- 10.1128/MCB.22.23.8226-8240.2002 · DOI · Paper page
- 10.1074/jbc.274.46.32738 · DOI · Paper page
- 10.1111/j.1399-3046.2005.00447.x · DOI · Paper page
- 10.1002/ana.21677 · DOI
- 10.1067/mpd.2003.201 · DOI
- 10.1016/S0387-7604(89)80083-X · DOI
- 10.1038/nrc1779 · DOI · Paper page
- Moser HW, 2005, Understanding and Treating Adrenoleukodystrophy. Present State and Future Perspectives, 28
- Moser HW, 2001, The Metabolic and Molecular Bases of Inherited Disease, 3257
- 10.1212/01.WNL.0000079460.21925.D3 · DOI
- Murphy JV, 1982, Treatment of adrenoleukodystrophy by diet and plasmapheresis, Ann Neurol, 12, 220
- 10.1006/mgme.2000.2977 · DOI
- 10.1182/blood-2003-10-3402 · DOI · Paper page
- 10.1016/j.ejpn.2007.11.006 · DOI
- 10.1093/jnen/59.2.89 · DOI · Paper page
- 10.1097/01.jnen.0000190064.28559.a4 · DOI · Paper page
- 10.1006/geno.2000.6367 · DOI
- 10.1016/j.ymgme.2003.09.002 · DOI
- 10.1016/j.freeradbiomed.2007.06.019 · DOI · Paper page
- 10.1038/nrneurol.2009.26 · DOI · Paper page
- 10.1007/s10545-008-0841-x · DOI · Paper page
- 10.1016/S0014-5793(98)00370-6 · DOI · Paper page
- 10.1056/NEJM199809033391012 · DOI · Paper page
- 10.1023/A:1022535930009 · DOI · Paper page
- 10.1042/BJ20091798 · DOI
- 10.1074/jbc.M205079200 · DOI · Paper page
- 10.1016/S0171-9335(98)80121-0 · DOI · Paper page
- 10.1136/jnnp.67.3.290 · DOI · Paper page
- 10.1016/j.bbadis.2003.10.004 · DOI
- 10.1002/1531-8249(200004)47:4<552::AID-ANA28>3.0.CO;2-0 · DOI
- 10.1038/nrd3031 · DOI · Paper page
- 10.1093/hmg/11.22.2701 · DOI · Paper page
- 10.1016/j.febslet.2005.09.014 · DOI · Paper page
- 10.1074/jbc.M509450200 · DOI · Paper page
- 10.1016/j.ejcb.2008.08.002 · DOI
- 10.1023/A:1005634130286 · DOI · Paper page
- 10.1196/annals.1427.023 · DOI · Paper page
Cited by
The epigenetic effects of butyrate: potential therapeutic implications for clinical practice
Berni Canani, R., Di Costanzo, M., & Leone, L. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-4 · Cited by 431
“Histone deacetylase inhibitors reduce the oxidative damage in X-ALD cells, moreover they could induce the expression of the closest homolog of ABCD1, the redundant gene ABCD2, which should be able to compensate for the lack of functional ABCD1 in X-ALD patients [36].”
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283
“For the majority of X-ALD patients, including males and females with AMN, as well as males with too advanced cerebral demyelinating disease for allogeneic HSC transplantation to be effective, treatment options are very limited andmostly symptomatic [103].”
Self-citationMetabolism of Very Long-Chain Fatty Acids: Genes and Pathophysiology
Sassa, T., & Kihara, A. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.017 · Cited by 302
“A defect in ABCD1 impairs the VLCFA degradation process, resulting in elevated levels of saturated C24-C26 VLCFAs in the plasma, brain, adrenal grand, and other tissues (Berger et al., 2010; Kemp et al., 2012).”
Pathophysiology of X-linked adrenoleukodystrophy
Berger, J., Forss-Petter, S., & Eichler, F. S. (2014) · Biochimie · doi:10.1016/j.biochi.2013.11.023 · Cited by 238
Self-citationThe physiological functions of human peroxisomes
Wanders, R. J. A., Baes, M., Ribeiro, D., Ferdinandusse, S., & Waterham, H. R. (2023) · Physiological Reviews · doi:10.1152/physrev.00051.2021 · Cited by 228
Metadata
- Authors
- Berger, J., Pujol, A., Aubourg, P., & Forss‐Petter, S.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2010-06-07
- Volume
- 20
- Issue
- 4
- Pages
- 845-856
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W2142167590
- Cited by
- 90
- References
- 45
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy. https://app.cochat.ai/papers/10.1111/j.1750-3639.2010.00393.x
- The paper
- Berger, J., Pujol, A., Aubourg, P., & Forss‐Petter, S. (2010). Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy. Brain Pathology. https://doi.org/10.1111/j.1750-3639.2010.00393.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.